Is GoHealth, Inc. overvalued or undervalued?

As of 13 May 2025, the valuation grade for GoHealth, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a P/E ratio of 6, an EV to EBITDA of 0.44, and a PEG ratio of 0.05, all of which suggest that the stock is trading at a substantial discount relative to its earnings and growth potential.
In comparison to peers, GoHealth's P/E ratio of 4.94 is notably lower than Crawford & Co.'s fair valuation P/E of 16.08, highlighting its undervaluation. Additionally, Hippo Holdings, Inc. is categorized as risky with a P/E of -13.62, further emphasizing GoHealth's relatively attractive position in the market. Despite recent underperformance against the S&P 500, with a year-to-date return of -59.75% compared to the index's 2.44%, the current valuation metrics suggest that GoHealth, Inc. presents a compelling investment opportunity.